Cabotegravir Plus Rilpivirine Injected Every 8 Weeks Seems S
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Cabotegravir plus rilpivirine given by injection every eight weeks appeared to be a promising new therapeutic option for people living with HIV at the 48-week mark in the ATLAS-2M trial. It is an ongoing, randomized, multicente, open-label, phase-3b non-inferiority study of cabotegravir plus rilpivirine long-acting maintenance therapy given intramuscularly every eight weeks or every four weeks to treatment-experienced adults.

The primary endpoint was the proportion of participants with plasma HIV-1 RNA of 50 copies/mL or more. A total of 1,045 participants were randomized to receive therapy every eight or four weeks, including 391 who transitioned from every four weeks in the phase-3 ATLAS study.

With respect to the primary endpoint, giving the injectable treatment every eight weeks (2%) was non-inferior to dosing every four weeks (1%), with an adjusted treatment difference of 0.8. Virologic failures, occurred in eight individuals in the every-eight-weeks group and two in the every-four-weeks group, the researchers reported.

The safety profile was similar between the dosing groups; 81% experienced adverse events; no treatment-related deaths occurred. Injection-site reactions, particularly pain, were the most common adverse events, affecting three-fourths of the participants. Overall, participants preferred the eight-week regimen.

Source:
1.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32666-0/fulltext
2.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32231-5/fulltext
Dr. T●●●●z H●●●●●●i and 1 others like this
Like
Comment
Share